{"Clinical Trial ID": "NCT00291577", "Intervention": ["INTERVENTION 1:", "- Sunitinib in combination with docetaxel", "Docetaxel (Taxotere) administered on the first day of each cycle by intravenous infusion (IV) every 3 weeks; initial dose of 75 mg/m2."], "Eligibility": ["Incorporation criteria:", "\u2022 Breast cancer with signs of non-resectable, locally recurrent or metastatic diseases", "\u2022 Candidate for docetaxel treatment", "- Exclusion criteria:", "Previous chemotherapy in the advanced framework of the disease", "Inflammatory breast cancer", "HER2 positive disease"], "Results": ["Performance measures:", "Time required to reach maximum plasma concentration (Tmax): Sunitinib (SU011248), Sunitinib Metabolitis (SU012662) and total PK parameters of the drug", "Median Tmax = time for maximum plasma concentration (Cmax) for SU011248, SU012662 and SU011248 combined and SU012662 (total drug); collected C1D2, C2D3. Coupled observation.", "Time: 1, 2, 4, 6, 8, 12, 24 hours after dose", "Results 1:", "- Arm/group title: Sunitinib in combination with Docetaxel", "Docetaxel (Taxotere) administered on day 1 of each cycle by intravenous infusion (IV) every 3 weeks; initial dose of 75 mg/m2.", "Total number of participants analysed: 11", "Median (full range)", "Unit of measurement: hours SU011248 C1D2: 6.0 (4.0 to 24.00)", "- SU011248 C2D3: 6.0 (2.0 to 8.0)", "- SU012662 C1D2: 6.0 (2.0 to 24)", "- SU012662 C2D3: 6.0 (4.0 to 24.0)", "Total drug C1D2: 6.0 (2.0 to 24.0)", "Total drug C2D3: 6.0 (2.0 to 8.0)"], "Adverse Events": ["Undesirable Events 1:", "Total: 11/22 (50%)", "- Febrile neutropenia 4/22 (18.18 per cent)", "- Leucopenia 1/22 (4.55%)", "Neutropenia 2/22 (9.09%)", "Stomatitis 1/22 (4.55%)", "Fatigue 1/22 (4.55%)", "Peripheral edema 1/22 (4.55%)", "Pyrexia 1/22 (4.55%)", "Yellowish index 1/22 (4.55%)", "Back pain 1/22 (4.55%)", "- Musculoskeletal pain 1/22 (4.55%)", "1/22 (4.55%)", "Headache 1/22 (4.55%)"]}